Biotech Values

[cjgaddy]

Patrick Crutcher, which interests your heart more, making some $$$ via shorting or desiring potential help for Cancer Victims? I don’t think there’s any doubt what’s #1 with you. …What a guy.

By PCrutch iHub/BVals #146814 8-9-12 3:12pm
“Well I am expecting triple failure of all their [Peregrine’s] trials this fall (NSCLC 1st & 2nd line, Pancreatic). I will be smiling then.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78376986

3-25-13 11:10am - Patrick Crutcher?@chasingthealpha
$PPHM failed 1L NSCLC trial should have OS reading out soon. Can’t wait for this epic fail - clinicaltrials.gov/ct2/show/NCT01160601?term=bavituximab
https://twitter.com/chasingthealpha/status/316250860470538240
.
.
- - - - - - - - - - - - - - - - - - - - - - - - - -
3-12-13 7:40amET: ”Peregrine's Bavituximab Future Looks Bleak”
By: Chimera Research Group (Patrick Crutcher)
Disclosure: I am short PPHM.
http://seekingalpha.com/article/1265341-peregrine-s-bavituximab-future-looks-bleak
.
.
AS OPPOSED TO . . .
1-11-2011: “Peregrine Seems Poised For Growth In 2011”
by Patrick Crutcher
Disclosure: Long PPHM
http://biomedreports.com/2011011162299/peregrine-poised-for-growth-in-2011.html
Back then you said you were LONG on PPHM, and you wrote,
“BAVITUXIMAB is an extremely interesting molecule which has created a lot of buzz over the past 2 years; not just in oncology but also as a potent anti-viral. . . PPHM entered into an ATM with MLV to the tune of $75 million. WE VIEW THIS DEAL POSITIVELY, since it allows them to raise capital as share price increases and it is not selling them at a discount to a fund. They have one of the best un-partnered pipelines amongst small-cap biotechs and WE ARE EXCITED ABOUT THE POTENTIAL OVER AT PEREGRINE.”